枸地氯雷他定与阿伐斯汀递减疗法治疗慢性荨麻疹的疗效比较

摘要

目的:比较枸地氯雷他定与阿伐斯汀递减疗法治疗慢性荨麻疹的疗效和安全性.方法:132例慢性荨麻疹患者随机分为A组(62例)和B组(70例).A组患者第1~2周口服枸地氯雷他定片8.8 mg,每日1次;第3~4周给予8.8 mg,每2日1次;第5~6周给予8.8 mg,每3日1次;第7~8周给予8.8 mg,每4日1次;第9~10周给予8.8 mg,每5日1次.B组患者第1~2周口服阿伐斯汀胶囊8 mg,每日3次;第3~4周给予8 mg,每日2次;第5~6周给予8 mg,每日1次;第7~8周给予8 mg,每2日1次;第9~10周给予8 mg,每3日1次.两组患者疗程均为10周.观察两组患者的临床疗效,治疗前后的血浆组胺水平和症状体征总积分,并随访两组患者停药4周后的复发情况及不良反应发生情况.结果:两组患者总有效率、不良反应发生率比较,差异均无统计学意义(P>0.05).治疗后,两组患者血浆组胺水平和症状体征总积分均显著低于同组治疗前,差异均有统计学意义(P0.05).A组患者复发率显著低于B组,差异均有统计学意义(P0.05). After treatment,the total scores of signs and symptoms in 2 groups were significantly lower than before,the difference was statistically significant(P0.05). The recurrence rate in group A was significantly lower than group B,the difference was sta-tistically significant(P<0.05). CONCLUSIONS:Both efficacy and safety of desloratadine citrate disodium and acrivastine decre-mental therapy in the treatment of chronic urticaria are good,however,desloratadine citrate disodium is better than acrivastine in re-ducing recurrence rate.